Comparison
AOD-9604 vs Selank
Side-by-side of AOD-9604 and Selank. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
AOD-9604
AOD 9604 peptide: 16-amino-acid hGH fragment 176-191. Preclinical lipolytic activity, phase 2 obesity trial showed no weight loss vs placebo.
Selank
Selank peptide benefits: tuftsin analog heptapeptide, intranasal anxiolytic and nootropic. Russian clinical data, dosing, half-life, safety.
Effects at a glance
AOD-9604
- •Modified 16-amino-acid synthetic fragment of human growth hormone (residues 176-191)
- •Preclinical models show lipolytic activity in adipose tissue without GH-axis growth effects
- •Phase 2 obesity trial (Heffernan 2001) showed no significant weight-loss difference versus placebo
- •Anecdotal protocols use 250 to 500 mcg subcutaneously daily on an empty stomach
- •No FDA approval; the obesity drug development program was discontinued in 2007
- •Granted GRAS status in some jurisdictions for compounded use; not validated for fat loss in humans
Selank
- •Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
- •Approved in Russia for generalized anxiety disorder and asthenic conditions
- •Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
- •Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
- •Most commonly administered intranasally; subcutaneous use is anecdotal
- •No Western-validated trials; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | AOD-9604 | Selank |
|---|---|---|
| Category | peptide | peptide |
| Also known as | hGH fragment 176-191, Human Growth Hormone Fragment 176-191 | TP-7, Tuftsin analog |
| Half-life (hr) ↗ | 0.5 | 0.5 |
| Typical dose (mg) ↗ | 0.3 | 0.4 |
| Dosing frequency | daily | 2-3x daily (intranasal) |
| Routes | subcutaneous | intranasal, subcutaneous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 2 | 1 |
| Molecular weight | 1815.17 | 751.85 |
| Molecular formula | C78H125N23O23S2 | C33H57N11O9 |
| Mechanism | Modified C-terminal fragment of human growth hormone proposed to stimulate beta-3 adrenergic receptor signaling in adipocytes, increasing lipolysis and fatty-acid oxidation without engaging the GH receptor or activating IGF-1. | Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity. |
| Legal status | Not FDA approved; research-use-only grey market in most jurisdictions | Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions |
| WADA status | unknown | unknown |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Insufficient data; not recommended | Not recommended; insufficient data |
| CAS | 221231-10-3 | 129954-34-3 |
| PubChem CID | 71300630 | 11765600 |
| Wikidata | Q4654106 | Q4416793 |
Safety profile
AOD-9604
Common side effects
- injection-site reactions
- transient mild headache (anecdotal)
- minimal in clinical trials
Contraindications
- pregnancy
- lactation
- no established human safety profile for chronic use
Interactions
- beta-blockers: theoretical antagonism of beta-3 adrenergic lipolytic signaling(minor)
Selank
Common side effects
- mild nasal irritation (intranasal)
- transient drowsiness (uncommon)
- mild headache
Contraindications
- pregnancy
- lactation
- severe psychiatric disorder (insufficient data)
Interactions
- benzodiazepines: additive anxiolytic effect; potential for over-sedation when stacked(moderate)
- SSRIs: no documented adverse interaction; co-administration described in Russian protocols(minor)
Which Should You Take?
Selank comes out ahead for most readers on the criteria we weight: 3 catalogued goals, research-only / gray-market sourcing, with a Tier-C outcome catalogued. AOD-9604 is the right call when one of the conditionals below applies.
- → If your priority is fat loss, pick AOD-9604.
- → If your priority is body composition, pick AOD-9604.
- → If your priority is focus or working memory, pick Selank.
- → If your priority is anxiety reduction, pick Selank.
Default choice: Selank. Wider use case, and broader goal coverage. Reach for AOD-9604 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between AOD-9604 and Selank?
AOD-9604 and Selank differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, AOD-9604 or Selank?
AOD-9604 half-life is 0.5 hours; Selank half-life is 0.5 hours.
Can you stack AOD-9604 with Selank?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper